MCID: CRB138
MIFTS: 42

Core Binding Factor Acute Myeloid Leukemia

Categories: Cancer diseases

Aliases & Classifications for Core Binding Factor Acute Myeloid Leukemia

MalaCards integrated aliases for Core Binding Factor Acute Myeloid Leukemia:

Name: Core Binding Factor Acute Myeloid Leukemia 25 69
Cbf Acute Myeloid Leukemia 25
Core-Binding Factor Aml 25
Cbf-Aml 25

Classifications:



Summaries for Core Binding Factor Acute Myeloid Leukemia

Genetics Home Reference : 25 Core binding factor acute myeloid leukemia (CBF-AML) is one form of a cancer of the blood-forming tissue (bone marrow) called acute myeloid leukemia. In normal bone marrow, early blood cells called hematopoietic stem cells develop into several types of blood cells: white blood cells (leukocytes) that protect the body from infection, red blood cells (erythrocytes) that carry oxygen, and blood cell fragments called platelets (thrombocytes) that are involved in blood clotting. In acute myeloid leukemia, the bone marrow makes large numbers of abnormal, immature white blood cells called myeloid blasts. Instead of developing into normal white blood cells, the myeloid blasts develop into cancerous leukemia cells. The large number of abnormal cells in the bone marrow interferes with the production of functional white blood cells, red blood cells, and platelets.

MalaCards based summary : Core Binding Factor Acute Myeloid Leukemia, also known as cbf acute myeloid leukemia, is related to acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2) and leukemia. An important gene associated with Core Binding Factor Acute Myeloid Leukemia is KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Cytarabine and Fludarabine have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and cellular

Related Diseases for Core Binding Factor Acute Myeloid Leukemia

Diseases related to Core Binding Factor Acute Myeloid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 70)
id Related Disease Score Top Affiliating Genes
1 acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2) 10.9 FLT3 KIT
2 leukemia 10.8
3 myeloid leukemia 10.8
4 malignant skin fibrous histiocytoma 10.6 HRAS KRAS
5 cask-related intellectual disability 10.6 FLT3 KIT RUNX1
6 epithelioid trophoblastic tumor 10.5 KIT WT1
7 limb ischemia 10.5 HRAS KRAS
8 epidermal nevus, somatic 10.5 HRAS NRAS
9 severe pre-eclampsia 10.5 HRAS KRAS
10 gastric papillary adenocarcinoma 10.5 HRAS KIT KRAS
11 breast adenoid cystic carcinoma 10.5 HRAS KIT KRAS
12 chronic polyneuropathy 10.5 HRAS NRAS
13 hypersensitivity reaction type iii disease 10.5 HRAS KIT KRAS
14 sublingual gland adenoid cystic carcinoma 10.5 HRAS KIT NRAS
15 vulval paget's disease 10.4 HRAS KIT NRAS
16 schimmelpenning-feuerstein-mims syndrome, somatic mosaic 10.4 HRAS KRAS NRAS
17 gastrointestinal neuroendocrine tumor 10.4 HRAS KIT KRAS
18 vaginal yolk sac tumor 10.4 HRAS KIT NRAS
19 thrombocythemia 3 10.4 FLT3 JAK2 KIT
20 occupational dermatitis 10.4 HRAS KRAS NRAS
21 hydrarthrosis 10.4 HRAS KIT NRAS
22 alopecia antibody deficiency 10.4 FLT3 KIT WT1
23 breast myoepithelial neoplasm 10.4 KRAS WT1
24 bone marrow cancer 10.4 HRAS KIT NRAS
25 ossifying fibromyxoid tumor 10.4 HRAS KRAS NRAS
26 heavy chain disease 10.4 HRAS KIT NRAS
27 anuria 10.4 ABCG2 HRAS KRAS
28 substance dependence 10.4 CSF1R KIT
29 proliferative glomerulonephritis 10.3 KIT NRAS WT1
30 dubin-johnson syndrome 10.3 HRAS KIT NRAS
31 nephrolithiasis 10.3 HRAS JAK2 NRAS
32 gallbladder cancer 10.3 HRAS KIT KRAS
33 non-distal trisomy 10q 10.3 HRAS KRAS NRAS
34 chronic venous leg ulcers 10.3 FLT3 JAK2 KIT RUNX1
35 lower gum cancer 10.3 ABCG2 WT1
36 pulmonary valve agenesis-tetralogy of fallot-absence of ductus arteriosus syndrome 10.3 CEBPA FLT3 KIT RUNX1
37 essential pentosuria 10.3 CEBPA FLT3 WT1
38 adenocarcinoma in situ 10.3 HRAS KRAS
39 coloboma of macula and skeletal anomalies 10.2 HRAS NRAS
40 brown-vialetto-van laere syndrome 10.2 HRAS KIT KRAS NRAS
41 fibrous meningioma 10.2 HRAS NRAS WT1
42 dental caries 10.2 HRAS KRAS WT1
43 orofaciodigital syndrome iv 10.2 HRAS KRAS NRAS
44 nasal cavity disease 10.2 HRAS KRAS WT1
45 leopard syndrome 1 10.1 HRAS KRAS NRAS
46 cutaneous liposarcoma 10.1 KIT TLE1 WT1
47 wilms tumor 6 10.1 KIT WT1
48 fallopian tube serous papilloma 10.1 KIT NRAS
49 gestational choriocarcinoma 10.0 KIT TLE1 WT1
50 acute pre-b-cell lymphoblastic leukemia 10.0 CEBPA FLT3 JAK2 KIT KRAS

Graphical network of the top 20 diseases related to Core Binding Factor Acute Myeloid Leukemia:



Diseases related to Core Binding Factor Acute Myeloid Leukemia

Symptoms & Phenotypes for Core Binding Factor Acute Myeloid Leukemia

GenomeRNAi Phenotypes related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.63 FLT3 CBL
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-117 10.63 KRAS
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.63 CEBPA FLT3 CBL WT1 KRAS
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.63 CEBPA CBL NRAS CSF3
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 10.63 CBL
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 10.63 KRAS
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-171 10.63 FLT3
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 10.63 FLT3 CBFB
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-187 10.63 FLT3
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 10.63 KRAS
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 10.63 CEBPA CBL NRAS CSF3 CBFB
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.63 KRAS
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.63 KRAS
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-28 10.63 NRAS
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 10.63 KRAS
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 10.63 CSF3
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 10.63 CBL
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-48 10.63 CEBPA
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.63 KRAS
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 10.63 CBFB
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 10.63 KRAS
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 10.63 CEBPA NRAS
23 Decreased viability GR00055-A-2 10.13 HRAS KRAS
24 Decreased viability GR00106-A-0 10.13 KRAS
25 Decreased viability GR00173-A 10.13 FLT3
26 Decreased viability GR00221-A-1 10.13 NRAS CSF1R HRAS FLT3 KIT KRAS
27 Decreased viability GR00221-A-2 10.13 HRAS KRAS
28 Decreased viability GR00221-A-3 10.13 NRAS HRAS
29 Decreased viability GR00221-A-4 10.13 CSF1R FLT3
30 Decreased viability GR00301-A 10.13 KIT KRAS
31 Decreased viability GR00381-A-1 10.13 KRAS
32 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.95 WT1 CBFB
33 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.95 FLT3
34 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.95 CBFB
35 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.95 FLT3
36 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.95 FLT3
37 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.95 FLT3 CEBPA
38 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.95 FLT3 CBL WT1 CBFB CEBPA
39 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.95 FLT3
40 Increased shRNA abundance (Z-score > 2) GR00366-A-13 9.95 CBFB
41 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.95 CBL
42 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.95 CBL
43 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.95 CBL
44 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.95 WT1
45 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.95 FLT3
46 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.95 CBFB
47 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.95 CBL CBFB
48 Increased shRNA abundance (Z-score > 2) GR00366-A-201 9.95 CBL
49 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.95 CBL
50 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.95 WT1
51 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.95 WT1
52 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.95 FLT3
53 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.95 WT1
54 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.95 WT1
55 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.95 CBFB
56 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.95 CBL WT1 CEBPA
57 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.95 WT1
58 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.95 FLT3
59 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.95 CBFB
60 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.95 CBL
61 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.95 WT1 CBFB CEBPA
62 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.95 CBFB
63 Increased cell migration GR00055-A-3 9.26 KRAS CSF1R HRAS CBL

MGI Mouse Phenotypes related to Core Binding Factor Acute Myeloid Leukemia:

44 (show all 19)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.39 RUNX1 WT1 RUNX2 CSF1R CBFB CEBPA
2 hematopoietic system MP:0005397 10.38 RUNX1 WT1 RUNX2 CSF1R CBFB CEBPA
3 endocrine/exocrine gland MP:0005379 10.37 WT1 RUNX2 CSF1R CEBPA JAK2 CBL
4 homeostasis/metabolism MP:0005376 10.37 RUNX2 RUNX1 WT1 HRAS CSF1R CBFB
5 growth/size/body region MP:0005378 10.36 RUNX2 RUNX1 WT1 HRAS CSF1R CBFB
6 immune system MP:0005387 10.36 RUNX1 WT1 RUNX2 CSF1R CBFB CEBPA
7 integument MP:0010771 10.31 RUNX2 CEBPA JAK2 CSF3 CBL ABCG2
8 cardiovascular system MP:0005385 10.28 RUNX2 RUNX1 WT1 HRAS CBFB CEBPA
9 mortality/aging MP:0010768 10.25 RUNX2 RUNX1 WT1 HRAS CSF1R CBFB
10 liver/biliary system MP:0005370 10.2 RUNX1 WT1 RUNX2 CEBPA JAK2 CBL
11 craniofacial MP:0005382 10.17 RUNX2 HRAS CSF1R CBFB CBL NRAS
12 no phenotypic analysis MP:0003012 10.15 WT1 RUNX2 CEBPA ABCG2 FLT3 KIT
13 neoplasm MP:0002006 10.1 RUNX1 WT1 CBFB HRAS CEBPA JAK2
14 normal MP:0002873 10.1 RUNX1 WT1 HRAS CSF1R CBFB CEBPA
15 limbs/digits/tail MP:0005371 10.02 RUNX2 CSF1R CBFB CBL NRAS KRAS
16 renal/urinary system MP:0005367 9.8 WT1 HRAS CEBPA CSF3 ABCG2 KRAS
17 reproductive system MP:0005389 9.76 RUNX2 WT1 CSF1R JAK2 CEBPA CBL
18 respiratory system MP:0005388 9.61 RUNX2 RUNX1 WT1 HRAS CBFB CEBPA
19 skeleton MP:0005390 9.32 RUNX2 RUNX1 HRAS CSF1R CBFB JAK2

Drugs & Therapeutics for Core Binding Factor Acute Myeloid Leukemia

Drugs for Core Binding Factor Acute Myeloid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 27)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147-94-4 6253
2
Fludarabine Approved Phase 4,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
3
Vidarabine Approved Phase 4,Phase 2,Phase 1 24356-66-9 32326 21704
4 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
5 Antimetabolites Phase 4,Phase 3,Phase 1,Phase 2
6 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 1,Phase 2
7 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2
8 Immunosuppressive Agents Phase 4,Phase 3,Phase 1,Phase 2
9
Daunorubicin Approved Phase 3,Phase 1,Phase 2 20830-81-3 30323
10
Dasatinib Approved, Investigational Phase 3,Phase 2,Phase 1 302962-49-8 3062316
11 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
12 Antibiotics, Antitubercular Phase 3,Phase 1,Phase 2
13 Topoisomerase Inhibitors Phase 3,Phase 1,Phase 2
14 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
15
Mitoxantrone Approved, Investigational Phase 2 65271-80-9 4212
16
Idarubicin Approved Phase 2,Phase 1 58957-92-9 42890
17
Lenograstim Approved Phase 2 135968-09-1
18
Alvocidib Experimental, Investigational Phase 2 146426-40-6, 131740-09-5 5287969
19 Analgesics Phase 2
20 Peripheral Nervous System Agents Phase 2
21 Adjuvants, Immunologic Phase 2
22
Busulfan Approved, Investigational 55-98-1 2478
23
Etoposide Approved 33419-42-0 36462
24
Vitamin C Approved, Nutraceutical 50-81-7 5785 54670067
25 Etoposide phosphate
26 Aclacinomycins
27 Antineoplastic Agents, Phytogenic

Interventional clinical trials:

(show all 14)

id Name Status NCT ID Phase Drugs
1 Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML Recruiting NCT02926586 Phase 4 Fludarabine;Cytarabine
2 Timed-Sequential Induction in CBF-AML Completed NCT00428558 Phase 3 Chemotherapy (DAUNORUBICINE-CYTARABINE);Chemotherapy (DAUNORUBICINE-CYTARABINE)
3 Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) Recruiting NCT02013648 Phase 3 Dasatinib;Cytarabine;Daunorubicin
4 Autologous Hematopoietic Cell Transplantation for Core-binding Factor (CBF) Acute Myeloid Leukemia (AML) in the First Complete Remission (CR1) Unknown status NCT01146977 Phase 2
5 Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia Completed NCT02113319 Phase 2 dasatinib
6 Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Completed NCT00850382 Phase 1, Phase 2 Dasatinib;daunorubicin;Cytarabine
7 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00407966 Phase 2 alvocidib;cytarabine;mitoxantrone hydrochloride
8 Fludarabine, Cytarabine, Filgrastim and Idarubicin in Core Binding Factor (CBF) Leukemias Recruiting NCT00801489 Phase 2 Fludarabine;Cytarabine;G-CSF (Filgrastim, Neupogen);Idarubicin
9 Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Recruiting NCT02971397 Phase 2 Cytarabine;Daunorubicin Hydrochloride
10 Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT01238211 Phase 2 Cytarabine;Dasatinib;Daunorubicin Hydrochloride
11 Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia Recruiting NCT02680951 Phase 1 Dasatinib;Fludarabine;Cytarabine;Idarubicin;Intrathecal (IT) cytarabine
12 Genome Wide SNP Array-based Approach to Detect Micro-cytogenetic Lesions and KIT Mutation to Improve Treatment Outcomes in Patients With Core-binding Factor Positive Acute Myeloid Leukemia Unknown status NCT01066286
13 Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia Recruiting NCT01050036
14 The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia Recruiting NCT03173612 Dasatinib

Search NIH Clinical Center for Core Binding Factor Acute Myeloid Leukemia

Genetic Tests for Core Binding Factor Acute Myeloid Leukemia

Anatomical Context for Core Binding Factor Acute Myeloid Leukemia

MalaCards organs/tissues related to Core Binding Factor Acute Myeloid Leukemia:

39
Myeloid, Bone, Bone Marrow, Eye

Publications for Core Binding Factor Acute Myeloid Leukemia

Articles related to Core Binding Factor Acute Myeloid Leukemia:

(show top 50) (show all 63)
id Title Authors Year
1
Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. ( 28494506 )
2017
2
D816V mutation in the KIT gene activation loop has greater cell-proliferative and anti-apoptotic ability than N822K mutation in core-binding factor acute myeloid leukemia. ( 28506695 )
2017
3
Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. ( 28556489 )
2017
4
KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia. ( 28792268 )
2017
5
Genetic abnormalities in core binding factor acute myeloid leukemia. ( 28883285 )
2017
6
D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations. ( 28762080 )
2017
7
Outcome of relapsed core binding factor acute myeloid leukemia in children: A result from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05R study. ( 28233452 )
2017
8
Stem Cell Modeling of Core Binding Factor Acute Myeloid Leukemia. ( 26880987 )
2016
9
Significance of KIT exon 17 mutation depends on mutant level rather than positivity in core-binding factor acute myeloid leukemia. ( 26771813 )
2016
10
Prognostic importance of c-kit mutations in core binding factor acute myeloid leukemia: A systematic review. ( 27613372 )
2016
11
Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia. ( 27298396 )
2016
12
Comprehensive mutational profiling of core binding factor acute myeloid leukemia. ( 26980726 )
2016
13
Predictive value of molecular remissions postconsolidation chemotherapy in patients with Core Binding Factor Acute Myeloid Leukemia (CBF-AML) - a single center analysis. ( 27597292 )
2016
14
Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. ( 26771376 )
2016
15
Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population. ( 25932436 )
2015
16
Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission. A French Acute Myeloid leukemia Intergroup trial. ( 25715404 )
2015
17
Core Binding Factor Acute Myeloid Leukemia: New Prognostic Categories and Therapeutic Opportunities. ( 26111469 )
2015
18
Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up. ( 25753065 )
2015
19
Additional chromosomal abnormalities in core-binding factor acute myeloid leukemia. ( 26681050 )
2015
20
Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center. ( 25449688 )
2014
21
Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis. ( 24793731 )
2014
22
Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors. ( 25348871 )
2014
23
High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML). ( 24844781 )
2014
24
Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy. ( 25088818 )
2014
25
Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup. ( 25006122 )
2014
26
Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia. ( 24972769 )
2014
27
Excess treatment reduction including anthracyclines results in higher incidence of relapse in core binding factor acute myeloid leukemia in children. ( 23677335 )
2013
28
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. ( 23321257 )
2013
29
Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease. ( 23646898 )
2013
30
Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation? ( 24319183 )
2013
31
The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. ( 23783394 )
2013
32
Prognosis of patients with core binding factor acute myeloid leukemia after first relapse. ( 23716553 )
2013
33
Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results. ( 23266036 )
2013
34
Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: screening and prognostic impact of c-KIT mutations. ( 24226631 )
2013
35
KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement. ( 23053179 )
2013
36
Impact of residual normal metaphases in core binding factor acute myeloid leukemia. ( 21928314 )
2012
37
High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations. ( 22234698 )
2012
38
A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia. ( 22886749 )
2012
39
Systemic mastocytosis is uncommon in KIT D816V mutation positive core-binding factor acute myeloid leukemia. ( 22145956 )
2012
40
Core-binding factor acute myeloid leukemia. ( 22032582 )
2011
41
Treatment strategies in patients with core-binding factor acute myeloid leukemia. ( 21755276 )
2011
42
Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia. ( 21715005 )
2011
43
Core binding factor acute myeloid leukemia (CBF-AML) in MAcxico: a single institution experience. ( 21574542 )
2011
44
Peripheral blasts on day 21 of induction chemotherapy in a patient with core binding factor acute myeloid leukemia: more than meets the eye. ( 20709669 )
2010
45
Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome. ( 19603346 )
2009
46
Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes. ( 19126873 )
2009
47
Rapid detection of KIT mutations in core-binding factor acute myeloid leukemia using high-resolution melting analysis. ( 19644024 )
2009
48
Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think? ( 19468270 )
2009
49
Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. ( 18841055 )
2008
50
Autologous stem cell transplantation with PCR-negative graft would be associated with a favorable outcome in core-binding factor acute myeloid leukemia. ( 18940681 )
2008

Variations for Core Binding Factor Acute Myeloid Leukemia

Expression for Core Binding Factor Acute Myeloid Leukemia

Search GEO for disease gene expression data for Core Binding Factor Acute Myeloid Leukemia.

Pathways for Core Binding Factor Acute Myeloid Leukemia

Pathways related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

(show top 50) (show all 85)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.88 CBL CSF1R CSF3 FLT3 HRAS JAK2
2
Show member pathways
13.66 CEBPA CSF1R CSF3 FLT3 HRAS JAK2
3
Show member pathways
13.56 CBL CSF1R FLT3 HRAS JAK2 KIT
4
Show member pathways
13.31 CSF1R CSF3 HRAS JAK2 KIT KRAS
5
Show member pathways
13.31 CEBPA CSF1R CSF3 FLT3 HRAS JAK2
6
Show member pathways
13.22 CBL CSF1R FLT3 HRAS KIT KRAS
7
Show member pathways
13.22 CBL CSF1R CSF3 FLT3 HRAS JAK2
8
Show member pathways
13.06 CSF1R HRAS JAK2 KIT KRAS NRAS
9
Show member pathways
12.92 CBL HRAS JAK2 KRAS NRAS
10
Show member pathways
12.85 CBL HRAS JAK2 KIT KRAS NRAS
11
Show member pathways
12.83 CBL HRAS JAK2 KRAS NRAS
12
Show member pathways
12.75 CSF1R HRAS KIT KRAS NRAS
13
Show member pathways
12.75 CBL HRAS KIT KRAS NRAS
14 12.6 CSF1R CSF3 HRAS JAK2 KIT KRAS
15 12.55 CBL CEBPA JAK2 KIT RUNX1
16
Show member pathways
12.53 CBL HRAS KRAS NRAS
17
Show member pathways
12.49 CBL HRAS JAK2 KRAS NRAS
18
Show member pathways
12.48 CBL HRAS JAK2 KRAS NRAS
19
Show member pathways
12.46 CBL FLT3 HRAS KRAS NRAS
20
Show member pathways
12.45 CBL HRAS KRAS NRAS
21
Show member pathways
12.44 CBL HRAS KRAS NRAS
22
Show member pathways
12.43 HRAS KIT KRAS NRAS
23
Show member pathways
12.42 CBL CEBPA HRAS JAK2
24
Show member pathways
12.41 CBL HRAS KRAS NRAS
25
Show member pathways
12.38 HRAS KIT KRAS NRAS
26
Show member pathways
12.37 CBL HRAS KRAS NRAS
27
Show member pathways
12.35 CBL HRAS KRAS NRAS
28
Show member pathways
12.34 CBL HRAS KRAS NRAS
29 12.32 CBL HRAS KRAS NRAS
30
Show member pathways
12.32 HRAS JAK2 KRAS NRAS
31
Show member pathways
12.29 CBL HRAS KRAS NRAS
32
Show member pathways
12.26 CSF1R HRAS KRAS NRAS
33
Show member pathways
12.24 HRAS JAK2 KRAS NRAS
34 12.21 CBL HRAS JAK2 KRAS
35
Show member pathways
12.2 CBL HRAS JAK2 KIT
36
Show member pathways
12.18 CBL FLT3 HRAS JAK2 KRAS NRAS
37
Show member pathways
12.16 CBL HRAS KRAS NRAS
38 12.11 HRAS JAK2 KRAS NRAS
39
Show member pathways
12.1 HRAS JAK2 KRAS NRAS
40
Show member pathways
12.09 CBL HRAS JAK2 KRAS
41
Show member pathways
12.08 CBL HRAS KRAS NRAS
42
Show member pathways
12.07 HRAS JAK2 KRAS NRAS
43 12.01 HRAS KRAS NRAS
44 12.01 CSF3 FLT3 KIT
45
Show member pathways
12.01 CBL CEBPA CSF1R FLT3 HRAS JAK2
46 12 HRAS KRAS NRAS
47 12 HRAS KRAS NRAS
48 11.99 HRAS KRAS NRAS
49 11.99 CEBPA CSF1R FLT3 RUNX1 RUNX2 WT1
50 11.98 HRAS KRAS NRAS

GO Terms for Core Binding Factor Acute Myeloid Leukemia

Biological processes related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 30)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.99 CEBPA CSF1R HRAS JAK2 WT1
2 positive regulation of gene expression GO:0010628 9.93 HRAS KIT KRAS RUNX2 TLE1
3 positive regulation of cell migration GO:0030335 9.88 CSF1R HRAS JAK2 KIT
4 axon guidance GO:0007411 9.88 CSF1R HRAS KRAS NRAS
5 protein autophosphorylation GO:0046777 9.86 CSF1R FLT3 JAK2 KIT
6 peptidyl-tyrosine phosphorylation GO:0018108 9.85 CSF1R FLT3 JAK2 KIT
7 MAPK cascade GO:0000165 9.85 HRAS JAK2 KIT KRAS NRAS
8 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.82 CSF1R FLT3 KIT
9 male gonad development GO:0008584 9.81 CBL KIT WT1
10 ossification GO:0001503 9.8 CBFB RUNX1 RUNX2
11 positive regulation of MAPK cascade GO:0043410 9.79 FLT3 HRAS KIT
12 Ras protein signal transduction GO:0007265 9.77 HRAS KRAS NRAS
13 positive regulation of cell proliferation GO:0008284 9.76 CSF1R CSF3 FLT3 HRAS JAK2 KIT
14 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.71 CSF1R FLT3 JAK2 KIT
15 ERBB2 signaling pathway GO:0038128 9.69 HRAS KRAS NRAS
16 cell maturation GO:0048469 9.67 CBFB CEBPA RUNX2
17 positive regulation of MAP kinase activity GO:0043406 9.67 FLT3 HRAS KIT KRAS
18 cellular response to cytokine stimulus GO:0071345 9.65 CSF1R CSF3 FLT3
19 hemopoiesis GO:0030097 9.65 CSF1R FLT3 KIT RUNX1 RUNX2
20 positive regulation of actin cytoskeleton reorganization GO:2000251 9.64 CSF3 HRAS
21 mast cell degranulation GO:0043303 9.63 CBL KIT
22 epidermal growth factor receptor signaling pathway GO:0007173 9.62 CBL HRAS KRAS NRAS
23 granulocyte differentiation GO:0030851 9.61 CEBPA CSF3
24 response to isolation stress GO:0035900 9.61 HRAS KRAS
25 myeloid progenitor cell differentiation GO:0002318 9.57 FLT3 KIT
26 macrophage differentiation GO:0030225 9.43 CEBPA CSF1R
27 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.35 CBL CSF3 FLT3 JAK2 KIT
28 cytokine-mediated signaling pathway GO:0019221 9.17 CEBPA CSF1R CSF3 FLT3 JAK2 KIT
29 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.07 CBFB CEBPA CSF3 HRAS RUNX1 RUNX2
30 transcription from RNA polymerase II promoter GO:0006366 10.03 CBFB CEBPA RUNX1 RUNX2 WT1

Molecular functions related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcription factor activity, sequence-specific DNA binding GO:0003700 9.8 CBFB CBL CEBPA RUNX1 RUNX2 WT1
2 ATP binding GO:0005524 9.8 ABCG2 CSF1R FLT3 JAK2 KIT RUNX1
3 nucleotide binding GO:0000166 9.35 HRAS JAK2 KIT KRAS NRAS
4 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.33 CSF1R FLT3 KIT
5 protein tyrosine kinase activity GO:0004713 8.92 CSF1R FLT3 JAK2 KIT

Sources for Core Binding Factor Acute Myeloid Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....